Disease · EFO_1001492
atrophic macular degeneration
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. atrophic macular degeneration. Diseases, record EFO_1001492. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001492
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- atrophic macular degeneration
- Open Targets ID
- EFO_1001492
- Other names
- dry macular degeneration, geographic atrophy
- Highest stage of its drugs
- Approval, for 2 of its 39 drugs, from FDA and TTD
Source Open Targets
Drugs39
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AVACINCAPTAD PEGOL | CHEMBL6068573 | Oligonucleotide | Approval | TTD | 8 | 6 | 6 | Drugs and targets |
| AVACINCAPTAD PEGOL SODIUM | CHEMBL4297889 | Approval | FDA | 1 | 0 | 0 | Drugs and targets | |
| PEGCETACOPLAN | CHEMBL4298211 | Protein | Phase 3 | ClinicalTrials.gov | 11 | 10 | 10 | Drugs and targets |
| LAMPALIZUMAB | CHEMBL2109408 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| POZELIMAB | CHEMBL4298086 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CEMDISIRAN | CHEMBL4297722 | Oligonucleotide | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TINLAREBANT | CHEMBL3967849 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EMIXUSTAT HYDROCHLORIDE | CHEMBL2107829 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| GILDEURETINOL | CHEMBL5314606 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 1 | 1 | Drugs and targets |
| AFLIBERCEPT | CHEMBL1742982 | Protein | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 39
See all 39 drugsTargets71
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| C5 | Complement C5 | 5 | Complement C5 binding agent; Complement C5 inhibitor; Complement C5 mRNA RNAi inhibitor | Approval | https://conductscience.org/library/genes/727 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha-2 | 2 | Adrenergic receptor alpha-2 agonist | Phase 2 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha-2 | 2 | Adrenergic receptor alpha-2 agonist | Phase 2 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha-2 | 2 | Adrenergic receptor alpha-2 agonist | Phase 2 | https://conductscience.org/library/genes/152 | Drugs and targets |
| C3 | Complement C3 | 2 | Complement C3 inhibitor | Phase 3 | https://conductscience.org/library/genes/718 | Drugs and targets |
| CFD | Complement factor D | 2 | Complement factor D inhibitor | Phase 3 | https://conductscience.org/library/genes/1675 | Drugs and targets |
| RPE65 | Retinoid isomerohydrolase | 2 | Retinoid isomerohydrolase inhibitor | Phase 2/3 | https://conductscience.org/library/genes/6121 | Drugs and targets |
| VEGFA | Vascular endothelial growth factor A, long form | 2 | Vascular endothelial growth factor A inhibitor | Phase 2/3 | https://conductscience.org/library/genes/7422 | Drugs and targets |
| APP | Amyloid-beta precursor protein | 1 | Amyloid-beta A4 protein binding agent | Phase 2 | https://conductscience.org/library/genes/351 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4697 | Drugs and targets |
1 to 10 of 71
See all 71 targetsTrials64
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02745119 | Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) | Phase 3 | 994 | 2019-02-15 | Geographic Atrophy | LAMPALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02247531 | A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | Phase 3 | 975 | 2019-03-14 | Geographic Atrophy | LAMPALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02247479 | A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | Phase 3 | 906 | 2019-04-23 | Geographic Atrophy | LAMPALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03525613 | A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration | Phase 3 | 637 | 2023-07-06 | Geographic Atrophy | PEGCETACOPLAN | Its record names the disease | ClinicalTrials.gov |
| NCT03525600 | Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration | Phase 3 | 621 | 2023-06-18 | Geographic Atrophy | PEGCETACOPLAN | Its record names the disease | ClinicalTrials.gov |
| NCT04435366 | A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) | Phase 3 | 448 | 2023-12-28 | Geographic Atrophy, Macular Degeneration | AVACINCAPTAD PEGOL | Its record names the disease | ClinicalTrials.gov |
| NCT03972709 | A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) | Phase 2 | 372 | 2024-03-27 | Macular Degeneration, Age-Related, Geographic Atrophy | GALEGENIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05019521 | A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | Phase 2 | 365 | 2025-09-05 | Geographic Atrophy | DANICOPAN | Its record names the disease | ClinicalTrials.gov |
| NCT02087085 | A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 2 | 310 | 2019-04-23 | Geographic Atrophy, Macular Degeneration | BRIMONIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT02686658 | Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2/3 | 286 | 2023-05-11 | Geographic Atrophy, Dry Age-Related Macular Degeneration | AVACINCAPTAD PEGOL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 64
See all 64 trialsComparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 400 µg Brimonidine Implant vs Sham: deaths from any cause | 5 of 154 | 6 of 156 | 310 | NCT02087085 | Trial comparisons |
| 400 µg Brimonidine Implant vs Sham: serious adverse events | 48 of 154 | 37 of 156 | 310 | NCT02087085 | Trial comparisons |
| ALK-001 vs Placebo: Number of Participants With Adverse Events | 97 of 135 | 52 of 63 | 198 | NCT03845582 | Trial comparisons |
| ALK-001 vs Placebo: deaths from any cause | 5 of 135 | 1 of 63 | 198 | NCT03845582 | Trial comparisons |
| ALK-001 vs Placebo: serious adverse events | 26 of 135 | 14 of 63 | 198 | NCT03845582 | Trial comparisons |
| Elamipretide vs Placebo: deaths from any cause | 2 of 117 | 0 of 59 | 176 | NCT03891875 | Trial comparisons |
| Elamipretide vs Placebo: serious adverse events | 18 of 117 | 6 of 59 | 176 | NCT03891875 | Trial comparisons |
| Metformin vs Observation: deaths from any cause | 0 of 32 | 2 of 34 | 66 | NCT02684578 | Trial comparisons |
| Metformin vs Observation: serious adverse events | 5 of 32 | 3 of 34 | 66 | NCT02684578 | Trial comparisons |
| Saline vs Eculizumab: serious adverse events | 0 of 20 | 0 of 40 | 60 | NCT00935883 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials51
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_1001492
GET https://conductscience.org/api/diseases/v1/EFO_1001492/drugs?page=2